Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy

Sponsor
Singapore National Eye Centre
Study ID
NCT00344617
Phase
PHASE3
Status
Unknown

Conditions

  • Choroidal Neovascularisation
  • Polypoidal Choroidal Vasculopathy

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To assess the use of Avastin for the management of serosanguinous maculopathy

Key Dates

First listed
Jun 27, 2006
Start date
Jun 30, 2006
Status verified
Sep 2007
Completion
May 31, 2008

Study Design

Enrollment
50 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Change from baseline in VA, i.e. gain or loss of 5 letters (1 line), 15 letters (3 lines) or 30 letters (6 lines)

Related Studies